Quest Pharmatech

Quest Pharmatech EV/FCF

The EV/FCF (Enterprise Value to Free Cash Flow) of Quest Pharmatech (QPT.V) as of Oct 27, 2026 is -26.60. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was -9.91 — a change of 168.39% (lower).

EV/FCF

-26.60

YoY

168.39%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of Quest Pharmatech is 2026 -26.60 . EV/FCF (Enterprise Value to Free Cash Flow) of Quest Pharmatech was 2025 -9.91 . It decreases by 168.39% lower compared to the previous year.

The Quest Pharmatech EV/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/FCF
Date
EV/FCF
Jan 1, 2019
-0.73 CAD
Jan 1, 2020
-0.79 CAD
Jan 1, 2021
-1.99 CAD
Jan 1, 2022
-29.71 CAD
Jan 1, 2023
-9.15 CAD
Jan 1, 2024
-14.82 CAD
Jan 1, 2025
-9.91 CAD
Jan 1, 2026
-26.60 CAD
The Quest Pharmatech EV/FCF history
YEAREV/FCFYoY
-26.60+168.39%
-9.91-33.11%
-14.82+61.99%
-9.15-69.21%
-29.71+1,394.98%
-1.99+151.15%
-0.79+7.75%
-0.73+6.14%
-0.69-37.03%
-1.10-44.61%
-1.98-43.41%
-3.51+15.83%
-3.03—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Quest Pharmatech Stock analysis

What does Quest Pharmatech do? Quest PharmaTech, Inc. operates as a biotechnology company headquartered in Edmonton, Alberta, focusing on the development and commercialization of antibody-based immunotherapeutic products for cancer. The firm aims to improve the quality of life through its proprietary MAb-AR9.6, which targets MUC16 as a diagnostic agent. This asset is licensed from the University of Nebraska Medical Centre and is currently in the late preclinical stage of development. The company generates value through strategic equity positions in specialized biotechnology entities. Quest PharmaTech holds a 42.5% ownership interest in OncoQuest Inc., a firm developing combinatorial immunotherapy products for cancer treatment. OncoQuest utilizes a technology platform featuring a panel of tumor antigen specific monoclonal antibodies of the immunoglobulin G and E class, targeting CA125, MUC1, PSA, Her2/neu, CA 19.9, and TAG72 to enhance tumor specific immunity. Additionally, the firm maintains a 23% ownership interest in OncoVent, which is developing antibody-based immunotherapeutic products for cancer within the Greater China territory. These investments allow Quest PharmaTech to extend its reach into specific geographic and therapeutic segments while leveraging the proprietary technologies and platforms of its partner companies. Quest Pharmatech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Quest Pharmatech stock

EV/FCF (Enterprise Value to Free Cash Flow) of Quest Pharmatech is -26.60 in 2026.

EV/FCF (Enterprise Value to Free Cash Flow) of Quest Pharmatech changed from -9.91 to -26.60, representing a 168.39% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) Quest Pharmatech since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s Quest Pharmatech with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Quest Pharmatech

All Key Metrics — Quest Pharmatech